EA201692513A1 - Ингибиторы лизин-специфической деметилазы-1 - Google Patents

Ингибиторы лизин-специфической деметилазы-1

Info

Publication number
EA201692513A1
EA201692513A1 EA201692513A EA201692513A EA201692513A1 EA 201692513 A1 EA201692513 A1 EA 201692513A1 EA 201692513 A EA201692513 A EA 201692513A EA 201692513 A EA201692513 A EA 201692513A EA 201692513 A1 EA201692513 A1 EA 201692513A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
compositions
compounds
lysine
specific
Prior art date
Application number
EA201692513A
Other languages
English (en)
Other versions
EA030946B1 (ru
Inventor
Юн К. Чэнь
Tоуфайк Каноуни
Джеффри Алан Стэффорд
Джеймс Марвин Вил
Original Assignee
Селджен Квонтисел Рисёрч, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938856&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692513(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Селджен Квонтисел Рисёрч, Инк. filed Critical Селджен Квонтисел Рисёрч, Инк.
Publication of EA201692513A1 publication Critical patent/EA201692513A1/ru
Publication of EA030946B1 publication Critical patent/EA030946B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

В целом, настоящее изобретение относится к композициям и способам лечения рака и неопластического заболевания. В настоящем документе предлагаются замещенные гетероциклические производные и фармацевтические композиции, содержащие указанные соединения. Заявленные соединения и композиции являются полезными для ингибирования лизин-специфической деметилазы-1. Кроме того, заявленные соединения и композиции являются полезными для лечения рака, такого как рак предстательной железы, рак молочной железы, рак мочевого пузыря, рак легких и/или меланома и т.п.
EA201692513A 2014-06-27 2015-06-26 Ингибиторы лизин-специфической деметилазы-1 EA030946B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462018365P 2014-06-27 2014-06-27
PCT/US2015/038089 WO2015200843A1 (en) 2014-06-27 2015-06-26 Inhibitors of lysine specific demethylase-1

Publications (2)

Publication Number Publication Date
EA201692513A1 true EA201692513A1 (ru) 2017-05-31
EA030946B1 EA030946B1 (ru) 2018-10-31

Family

ID=54938856

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692513A EA030946B1 (ru) 2014-06-27 2015-06-26 Ингибиторы лизин-специфической деметилазы-1

Country Status (27)

Country Link
US (3) US10011583B2 (ru)
EP (1) EP3160956B1 (ru)
JP (2) JP6587241B2 (ru)
KR (1) KR102438302B1 (ru)
CN (1) CN106660987B (ru)
AU (2) AU2015279591A1 (ru)
BR (1) BR112016030697B1 (ru)
CA (1) CA2953810C (ru)
CL (1) CL2016003350A1 (ru)
CO (1) CO2017000362A2 (ru)
CY (1) CY1123475T1 (ru)
DK (1) DK3160956T3 (ru)
EA (1) EA030946B1 (ru)
EC (1) ECSP17005635A (ru)
ES (1) ES2812626T3 (ru)
HR (1) HRP20201337T1 (ru)
HU (1) HUE050564T2 (ru)
IL (1) IL249733B (ru)
LT (1) LT3160956T (ru)
MX (1) MX2017000179A (ru)
PL (1) PL3160956T3 (ru)
PT (1) PT3160956T (ru)
RS (1) RS60658B1 (ru)
SG (2) SG10201911220TA (ru)
SI (1) SI3160956T1 (ru)
WO (1) WO2015200843A1 (ru)
ZA (1) ZA201700069B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ716427A (en) 2013-08-06 2021-07-30 Imago Biosciences Inc Kdm1a inhibitors for the treatment of disease
WO2015200843A1 (en) 2014-06-27 2015-12-30 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
EP3511319B1 (en) * 2014-07-03 2023-05-03 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
WO2016130952A1 (en) 2015-02-12 2016-08-18 Imago Biosciences, Inc. Kdm1a inhibitors for the treatment of disease
MX2017015922A (es) 2015-06-12 2018-12-11 Oryzon Genomics Sa Biomarcadores asociados con inhibidores de lsd1 y usos de los mismos.
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CA3017411A1 (en) 2016-03-15 2017-09-21 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US11390590B2 (en) 2016-08-16 2022-07-19 Imago Biosciences, Inc. Methods and processes for the preparation of KDM1A inhibitors
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
JP2020121925A (ja) * 2017-04-10 2020-08-13 三井化学アグロ株式会社 ピリドン化合物とキノリン系化合物を含有する有害生物防除組成物および有害生物の防除方法、ならびに新規キノリン系化合物
WO2018190324A1 (ja) * 2017-04-10 2018-10-18 三井化学アグロ株式会社 ピリドン化合物を有効成分として含有する抗真菌剤およびその使用方法
WO2018190323A1 (ja) * 2017-04-10 2018-10-18 三井化学アグロ株式会社 ピリドン化合物と有害生物防除剤を含有する有害生物防除組成物および有害生物の防除方法
JP2020529995A (ja) 2017-08-03 2020-10-15 オリゾン ジェノミックス ソシエダッド アノニマ 行動の変化の治療方法
RU2020133727A (ru) * 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
JP7450559B2 (ja) 2018-05-11 2024-03-15 イマーゴ バイオサイエンシーズ インコーポレイテッド 疾患の処置のためのｋｄｍ１ａ阻害剤
KR20210141933A (ko) 2019-03-20 2021-11-23 오리존 지노믹스 에스.에이. 경계성 인격 장애의 치료 방법
EP3941465A1 (en) 2019-03-20 2022-01-26 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
KR20230167102A (ko) 2021-04-08 2023-12-07 오리존 지노믹스 에스.에이. 골수성 암 치료를 위한 lsd1 억제제의 조합물
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1861399B1 (en) * 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
JP2009541321A (ja) 2006-06-21 2009-11-26 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 細胞増殖阻害剤としてのピラジノン
JP5140154B2 (ja) * 2007-06-27 2013-02-06 アストラゼネカ・アクチエボラーグ ピラジノン誘導体および肺疾患の処置におけるそれらの使用
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2012013727A1 (en) * 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
SG11201408324QA (en) * 2012-06-12 2015-01-29 Abbvie Inc Pyridinone and pyridazinone derivatives
WO2015089192A1 (en) * 2013-12-11 2015-06-18 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
WO2015200843A1 (en) 2014-06-27 2015-12-30 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1

Also Published As

Publication number Publication date
JP2017519781A (ja) 2017-07-20
AU2015279591A1 (en) 2017-01-19
KR20170018913A (ko) 2017-02-20
CY1123475T1 (el) 2022-03-24
CA2953810C (en) 2022-07-12
CO2017000362A2 (es) 2017-04-10
CN106660987B (zh) 2020-11-06
US20200172506A1 (en) 2020-06-04
IL249733A0 (en) 2017-02-28
RS60658B1 (sr) 2020-09-30
DK3160956T3 (da) 2020-08-31
CA2953810A1 (en) 2015-12-30
EP3160956A4 (en) 2018-01-10
US11028066B2 (en) 2021-06-08
AU2019261771B2 (en) 2020-09-24
SI3160956T1 (sl) 2020-11-30
PL3160956T3 (pl) 2020-11-30
US20170137402A1 (en) 2017-05-18
US10011583B2 (en) 2018-07-03
ECSP17005635A (es) 2017-03-31
JP2019167345A (ja) 2019-10-03
HUE050564T2 (hu) 2020-12-28
JP6851418B2 (ja) 2021-03-31
JP6587241B2 (ja) 2019-10-09
SG10201911220TA (en) 2020-02-27
HRP20201337T1 (hr) 2020-11-27
LT3160956T (lt) 2020-09-10
BR112016030697B1 (pt) 2023-03-21
BR112016030697A2 (pt) 2018-07-17
EP3160956A1 (en) 2017-05-03
KR102438302B1 (ko) 2022-08-30
IL249733B (en) 2020-07-30
EP3160956B1 (en) 2020-05-27
SG11201610866PA (en) 2017-01-27
CN106660987A (zh) 2017-05-10
AU2019261771A1 (en) 2019-11-28
ES2812626T3 (es) 2021-03-17
PT3160956T (pt) 2020-09-01
ZA201700069B (en) 2018-04-25
WO2015200843A1 (en) 2015-12-30
US20180273505A1 (en) 2018-09-27
EA030946B1 (ru) 2018-10-31
CL2016003350A1 (es) 2018-05-11
US10597376B2 (en) 2020-03-24
MX2017000179A (es) 2017-05-01

Similar Documents

Publication Publication Date Title
EA201692513A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790376A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201591145A1 (ru) Ингибиторы гистондеметилазы
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201790317A1 (ru) Ингибиторы smyd
EA201691940A1 (ru) Новые соединения
CR20200362A (es) CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
EA201790603A1 (ru) Ингибиторы гистондеметилазы
EA201790327A1 (ru) Соединения замещенного пиперидина
EA201692470A1 (ru) Фармацевтические комбинации
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201790604A1 (ru) Ингибиторы гистондеметилазы
EA201990556A1 (ru) Ингибиторы клеточных метаболических процессов
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam